DelveInsight Business Research, LLP: DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...
Dermatology Advisor3d
AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
Ivarmacitinib at both 4 mg and 8 mg doses was found to be efficacious in treating alopecia areata in a phase 3 trial.